These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 33987350)

  • 1. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.
    Xie D; Sun Q; Wang X; Zhou J; Fan J; Ren Z; Gao Q
    Ann Transl Med; 2021 Apr; 9(8):652. PubMed ID: 33987350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world.
    Feng JK; Liu ZH; Fu ZG; Chai ZT; Sun JX; Wang K; Cheng YQ; Zhu HF; Xiang YJ; Zhou LP; Shi J; Guo WX; Zhai J; Cheng SQ
    Front Oncol; 2022; 12():954203. PubMed ID: 36505818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
    Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
    Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
    Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
    Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
    Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
    Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
    World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
    Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
    Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
    Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience.
    Pan X; Wu SJ; Tang Y; Zhou YF; Luo JW; Fang ZT
    J Hepatocell Carcinoma; 2023; 10():883-892. PubMed ID: 37324411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.
    Pang B; Zuo B; Huang L; You X; Liu T; Hao J; Yuan C; Yang C; Yee Lau W; Zhang Y
    Int Immunopharmacol; 2024 Aug; 137():112492. PubMed ID: 38906005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.
    Li J; Kong M; Yu G; Wang S; Shi Z; Han H; Lin Y; Shi J; Song J
    Front Immunol; 2023; 14():1188308. PubMed ID: 37545497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.
    Yuan G; Li W; Zang M; Li R; Li Q; Hu X; Zhang Q; Huang W; Ruan J; Pang H; Chen J
    Discov Oncol; 2024 Mar; 15(1):68. PubMed ID: 38460053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Cao F; Yang Y; Si T; Luo J; Zeng H; Zhang Z; Feng D; Chen Y; Zheng J
    Front Oncol; 2021; 11():783480. PubMed ID: 34988019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
    Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
    J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
    Teng Y; Ding X; Li W; Sun W; Chen J
    Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
    [No Abstract]   [Full Text] [Related]  

  • 16. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
    Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
    Front Oncol; 2022; 12():980214. PubMed ID: 36249023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
    Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
    EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
    Cai M; Huang W; Liang W; Guo Y; Liang L; Lin L; Xie L; Zhou J; Chen Y; Cao B; Wu J; Zhu K
    Liver Int; 2024 Apr; 44(4):920-930. PubMed ID: 38291865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.
    Hu Y; Pan T; Cai X; He QS; Zheng YB; Huang MS; Jiang ZB; Chen JW; Wu C
    J Gastrointest Oncol; 2023 Aug; 14(4):1837-1848. PubMed ID: 37720446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Li SQ; Wu JY; Wu JY; Xie H; Li JH; Zeng ZX; Fu YK; Liu DY; Li H; Chen WZ; Huang JY; Yan ML
    J Hepatocell Carcinoma; 2023; 10():1799-1811. PubMed ID: 37850080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.